EN

Your shopping cart

Amount

Total (VAT incl.)

VAT (21%)
Total
You have not added any reports to the cart yet.
Request reports
If you prefer to place your order via e-mail
contact us at: digital@azierta.com

Events and news

Blog
Home > Blog > Pharmacovigilance

Development Update Safety Report

According to ICH guideline E2F (Step 5) on Development Safety Update Reports (DSURs) already implemented since 2011, companies must submit DSURs on a yearly basis for medicinal products involved in clinical trials. The focus of the DSUR is on data and findings from clinical trials of drugs and biologicals, whether they are authorized or not.

DSURs are internationally-harmonized, safety documents covering the safety summary of medicinal products during their development or clinical trial phase.

They are based heavily on the PSUR format already used for updating the safety record of drugs in their marketing phase.

A DSUR should be prepared after the first authorization of a clinical trial worldwide. A copy of the DSUR should be submitted to each concerned European Member State (MS) if a clinical trial is authorized in this MS for this investigational drug (still using the DIBD). Therefore, the first DSUR can be submitted to a concerned MS earlier than 1 year, but the covered reporting period should not be longer than 1 year.

The DSUR presents an annual review & evaluation of safety information:

  • Information reported during the current review period and analysis based on previous knowledge of the products’ safety
  • Description of new issues that may impact the overall program or specific clinical trials.
  • Summarization of current understanding and management of known and potential safety risks to exposed patients.
  • Provide an update on the status of the clinical development program.

In Azierta, scientific and healthcare consulting, we are experts in Pharmacovigilance and we have a team of highly qualified drug safety experts who support our clients to manage pharmacovigilance in an optimal way. Our work covers all areas of pharmacovigilance, both at the level of medicines, as well as medical devices and cosmetic products.

If you are interested in the contents of the good practices of pharmacovigilance (GVPs), as well as in other products related to pharmacovigilance visit our safety reports website for more details and feel free to contact us, we will be pleased to help you.

Back

Related posts

Updated guidance on pharmacovigilance procedures

On September 1st, the Medicines and Healthcare products Regulatory Agency (MHRA) published a pharmacovigilance update for...

Read more

Development Safety Update Report (DSUR)

In September 2010, the International Conference Harmonisation developed the ICH E2F Guideline for the Development Safety...

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience

Innovation

Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76
Schedule appointment

Schedule a video call with our field experts

schedule
We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.